The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 56 , ISSUE 4 ( October-December, 2014 ) > List of Articles


Multidrug Resistant Tuberculosis: Trends and Control

Rajendra Prasad, Mandeep Singh

Keywords : Tuberculosis, MDR-TB, Trends

Citation Information : Prasad R, Singh M. Multidrug Resistant Tuberculosis: Trends and Control. Indian J Chest Dis Allied Sci 2014; 56 (4):237-246.

DOI: 10.5005/ijcdas-56-4-237

License: CC BY-NC 4.0

Published Online: 28-06-2022

Copyright Statement:  Copyright © 2014; The Author(s).


Multidrug resistant tuberculosis (MDR-TB) has been an area of growing concern and is posing a threat to the control of tuberculosis (TB). The exact magnitude of problem of resistance to anti-tuberculosis drugs worldwide was not known till the 1994-97 global project on anti-tuberculosis drug resistance surveillance initiated by the World Health Organization (WHO) and International Union Against Tuberculosis and Lung Diseases (IUATLD). The Global Tuberculosis Report 2014 estimated that an 3.5% of newly diagnosed and 20.5% of previously treated TB cases had MDR-TB. It has been estimated that 480,000 cases emerged and 210,000 deaths occurred due to MDR-TB globally in 2013. In India, estimates showed that the prevalence of MDR-TB among new and previously treated patients was 2.2% and 15%, respectively. It is estimated that 99,000 cases of MDR-TB emerge every year of which 62,000 were among notified cases of TB in 2013. The MDR-TB is a human-made problem and results largely from poorly managed cases of TB. Adequate, timely diagnosis and optimal treatment of MDR-TB will help curb the epidemic. Efforts must be focused on the effective use of anti-tuberculosis drugs in every new patient, so as to prevent the emergence of MDR-TB.

PDF Share
  1. Jawahar MSS. Multidrug resistant tuberculosis. ICMR Bull 1999;29:105-14.
  2. Cohn DL, Bustreo F, Raviglione MC. Drug resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997;24:S121-30.
  3. Pablos-Mendez A, Raviglione MC, Laszlo A, Biokin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis drug resistance, 1994-1997. World Health Organization–International Union Against Tuberculosis and Lung Disease Working Group on Antituberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-9.
  4. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294-303.
  5. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug resistant tuberculosis. J Infect Dis 2002;185:1197-202.
  6. WHO-IUATLD. Global Project on antituberculosis drug resistance surveillance. Antituberculosis drug resistance in the world. Report No. 2, prevalence and trends. WHO/CDS/TB/2000. 278. Geneva: WHO; 2000.
  7. Dye C, William BG, Espinal MA, Raviglione MC. Erasing the world's slow strain: strategies to beat multidrug-resistant tuberculosis. Science 2002;295:2042-6.
  8. National Tuberculosis Programme. Tuberculosis in Latvia 1991-2000. Riga 2001; 21-3.
  9. Robert J, Trystram D, Pernot-Truffot C, Jarlier V. Surveillance de la tuberculose a bacilles multiresistants en France en 1998. Bull Epidemiol Hebdo 2002;16:71-2.
  10. Robert J, Trystram D, Pernot-Truffot C, Carbonelle B. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. Int J Tuberc Lung Dis 2000;4:665-72.
  11. Centers for Disease Control. Reported tuberculosis in the United States 2000. Atlanta, GA: US Department of Health and Human Services, CDC, August 2001.
  12. WHO-IUALTD Global Project on Antituberculosis Drug Resistance Surveillance (1999-2002). Third Global Report. Geneva: WHO; 2003.
  13. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-85.
  14. WHO-IUALTD Global Project on Antituberculosis Drug Resistance Surveillance (2002-2007). Fourth Global Report. 2008, updated 2010.
  15. Zignol M, Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 2012;90:111-9.
  16. World Health Organization. Global tuberculosis report 2012. WHO/HTM/TB/2012.6.
  17. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11
  18. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB/2014.08
  19. Indian Council of Medical Research. Prevalence of drug resistance in patients with pulmonary tuberculosis presenting for the first time with symptoms at chest clinics in India. II. Findings in urban clinics among all patients, with or without history of previous chemotherapy. Indian J Med Res 1969;57:823-35.
  20. Krishnaswamy KV, Rahim MA. Primary drug resistance in pulmonary tuberculosis. Indian J Chest Dis 1976;28:233-7.
  21. Trivedi SS, Desai SC. Primary antituberculosis drug resistance and acquired rifampicin resistance in Gujarat, India. Tubercle 1988;69:37-42.
  22. Chandrasekaran S, Chauhan MM, Rajalaksmi R, Chaudhuri K, Mahadev B. Initial drug resistance to antituberculosis drugs in patients attending an urban district tuberculosis centre. Indian J Tub 1990;37:215-6.
  23. Chandrasekaran S, Jagota P, Chaudhuri K. Initial drug resistance to antituberculosis drugs in urban and rural district tuberculosis programme. Indian J Tub 1992;39:171-5.
  24. Paramasivan CN, Chandrasekaran V, Santha T, Sudarsanam NM, Prabhakar R. Bacteriological investigations for short course chemotherapy under the tuberculosis programme in two districts in India. Tuber Lung Dis 1993;74:23-7.
  25. Gupta PR, Singhal B, Sharma TN, Gupta RB. Prevalence of initial drug resistance in tuberculosis patients attending a chest hospital. Indian J Med Res 1993;97:102-3.
  26. Jain NK, Chopra KK, Prasad G. Initial and acquired isoniazid and rifampicin resistance to M. tuberculosis and its implications for treatment. Indian J Tub 1992;39:121-4.
  27. Jena J, Panda BN, Nema SK, Ohri VC, Pahwa RS. Drug resistance pattern of Mycobacterium tuberculosis in a chest disease hospital of armed forces. Lung India 1995;13:56-9.
  28. Parmasivan CN, Bhaskaran K, Venkataraman, Chandrasekhran V, Narayanan PR. Surveillance of drug resistance in tuberculosis in the state of Tamil Nadu. Indian J Tub 2000;47:27-33.
  29. Prasad R, Suryakant, Mukerji PK, Gupta AK, Garg R, Rizvi DM, et al. Initial drug resistance in patients of pulmonary tuberculosis attending a tertiary care centre. Indian J Tub 2001;48:159.
  30. Paramasivan CN, Venkataraman P, Chandrashekhran V, Bhatt S, Narayanan PR. Surveillance of drug resistant in tuberculosis in two districts of south India. Int J Tuberc Lung Dis 2002;6:479-84.
  31. Sofia V, Balasangameshwara VH, Jagannatha PS, Kumar P. Initial drug resistant among tuberculosis patients under DOTS programme in Banglore city. Indian J Tub 2004; 52:17-21.
  32. Mahadeo B, Kumar P, Agrawal SP, Chauhan LS, Sriknataramu N. Surveillance of drug resistant to antituberculosis drugs in districts of Hoogli in West Bengal and Myurbhanj in Orissa. Indian J Tub 2005;52:5-10.
  33. Jain A, Mondal R, Prasad R, Singh K, Ahuja RC. Prevalence of multidrug resistant mycobacterium tuberculosis in Lucknow, Uttar Pradesh. Indian J Med Res 2008;128:300-6.
  34. Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis 2009;13:1154-60.
  35. Datta M, Radhamani MP, Selvaraj R, Paramasivan CN, Gopalan BN, Sudeendra CR, et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tuber Lung Dis 1993;74:180-6.
  36. Chowgule RV, Deodhar L. Pattern of secondary acquired drug resistance to antituberculosis drug in Mumbai, India 1991–1995. Indian J Chest Dis Allied and Sci 1998;40:23-31.
  37. Shah AR, Agarawal SK, Shah KV. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. Int J Tuberc Lung Dis 2002;6:1098-101.
  38. Deivanayagam CN, Rajasekaran S, Venkatesan R, Mahilmaran A, Ahmed PR, Annadurai S, et al. Prevalence of acquired MDR-TB and HIV coinfection. Indian J Chest Dis Allied Sci 2002;44:237-42.
  39. Prasad R, Suryakant, Mukerji PK, Gupta AK, Garg R, Rizvi DM, et al. Acquired drug resistance in patients of pulmonary tuberculosis attending a tertiary care center. Int J Tuberc Lung Dis 2003;11 (Suppl.):S3O3.
  40. Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 2010;14:243-6.
  41. Prasad R, Verma SK, Garg R, Jain A, Anand SC, Hosmane GB, et al. Drug susceptibility pattern of Mycobacterium tuberculosis isolates from patients of Category- II failure of pulmonary tuberculosis under directly observed treatment short-course from North India. Biosci Trends 2012;6:110-4.
  42. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-21.
  43. Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L, et al. An outbreak of multidrug-resistant tuberculosis involving HIV infected patients of two hospitals in Milan, Italy. AIDS 1998;12:1095-1102.
  44. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999;3:4-11.
  45. Chum HJ, O'Brien RJ, Chonde TM, Graf P, Rieder HL. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS 1996;10:299-309.
  46. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6.
  47. Coronado VG, Beck-Sague CM, Hutton MD, Davis BJ, Nicholas P, Villareal C, et al. Transmission of multidrugresistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993;168:1052-5.
  48. Busillo CP, Lessnau KD, Sanjana V, Soumakis S, Davidson M, Mullen MP, et al. Multidrug-resistant Mycobacterium tuberculosis in patients with human immunodeficiency virus infection. Chest 1992;102:797-801.
  49. Shafer RW, Small PM, Larkin C, Singh SP, Kelly P, Sierra MF, et al. Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York city: a molecular epidemiologic assessment. J Infect Dis 1995;152:171-6.
  50. Mac-Arthur A, Gloyd S, Perdigão P, Noya A, Sacarlal J, Kreiss J. Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. Int J Tuberc Lung Dis 2001;5:894-902.
  51. Prasad R. multidrug resistant tuberculosis and existing health system in India (Editorial). Chest (Indian Edition) 2011;3:65-7.
  52. Kant S, Maurya AK, Kushwaha RA, Nag VL, Prasad R. Multi-drug resistant tuberculosis: an iatrogenic problem. Biosci Trends 2010;4:48-55.
  53. Prasad R. MDR TB: current status. Indian J Tub 2005; 52:121-31.
  54. Philip CH, Madhukar P, Dermot M, Mukund U, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006;6:710-25.
  55. Prasad R, Nautiyal RG, Mukherji PK, Jain A, Singh K, Ahuja RC. Treatment of new pulmonary tuberculosis patients: what do allopathic doctors do in India? Int J Tuberc Lung Dis 2002;6:895-902.
  56. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short course chemotherapy for drug resistant tuberculosis: treatment outcome in six countries. JAMA 2000;283:2537-45.
  57. Prasad R. Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions. Indian J Tub 2010;57:180-91.
  58. DOTS-Plus and Green Light Committee. Available at: Accessed on June 1, 2014.
  59. The Global MDR-TB & XDR-TB response Plan 2007-2008. World Health Organization Document, 2007 WHO/HTM/TB/2007.387.
  60. Stop TB Partnership and World Health Organization. The Global Plan to Stop TB 2006–2015. Geneva: World Health Organization; 2006.
  61. WHO Global XDR-TB task force meeting, Oct 2006. Available at: Accessed on June 1, 2014.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.